Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,358 result(s) found. Displaying page 1,728 of 2,218.
    «« First « Previous 1724  1725  1726  1727  1728  1729  1730  1731  1732  Next» Last»»
    EudraCT Number: 2020-002819-21 Sponsor Protocol Number: GWND19189 Start Date*: Information not available in EudraCT
    Sponsor Name:GW Research Ltd
    Full Title: An exploratory, Phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (GWP42003-P; CBD-OS) in children and adolescents with...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001773-17 Sponsor Protocol Number: FGCL-4592-082 Start Date*: 2017-11-06
    Sponsor Name:FibroGen, Inc.
    Full Title: A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome...
    Medical condition: Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with <5% Blasts, and has low red blood cell transfusion burden ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Completed) DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004593-29 Sponsor Protocol Number: Uni-Koeln-1495 Start Date*: 2016-01-19
    Sponsor Name:University of Cologne
    Full Title: Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma
    Medical condition: recurrent or progressive high-risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003827-31 Sponsor Protocol Number: ICO-N-2017-08 Start Date*: 2018-07-16
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial
    Medical condition: oligometastatic hormone sensitive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007463 Carcinoma prostatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001534-19 Sponsor Protocol Number: APHP200015 Start Date*: 2021-05-21
    Sponsor Name:AP-HP/DRCI
    Full Title: Direct oral Anticoagulants for Prevention of lEft ventRIcular Thrombus after anterior acute myocardial InFarction
    Medical condition: Left ventricular (LV) thrombus after acute myocardial infarction (AMI)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001430-35 Sponsor Protocol Number: 35RC19_8860_FLUDROSEPSIS Start Date*: 2021-04-21
    Sponsor Name:CHU Rennes
    Full Title: Evaluation of the hemodynamic effects of fludrocortisone on the pressive response to norepinephrine in patients in septic shock
    Medical condition: septic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004163-47 Sponsor Protocol Number: AS0014 Start Date*: 2020-06-16
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylo...
    Medical condition: Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BG (Completed) BE (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001595-15 Sponsor Protocol Number: 270389-010520 Start Date*: 2020-06-23
    Sponsor Name:Henrik Birn
    Full Title: The Measures to Optimize RAAS-blockade in Patients with Hyperkalemia and Chronic Kidney Disease
    Medical condition: Chronic kidney disease with albuminuria
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10020647 Hyperkalemia LLT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001507-76 Sponsor Protocol Number: BRONCHIOLE2017 Start Date*: 2017-09-20
    Sponsor Name:Region Örebro län
    Full Title: Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) A pragmatic clinical trial with partial registry-based follow-up
    Medical condition: Chronic Obstructive Pulmonary disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004287-56 Sponsor Protocol Number: CHUBX2016/44 Start Date*: 2019-11-21
    Sponsor Name:CHU de Bordeaux
    Full Title: Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study
    Medical condition: rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004971-42 Sponsor Protocol Number: RVT-1201-2002 Start Date*: 2021-10-26
    Sponsor Name:Altavant Sciences GmbH
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Prematurely Ended) FR (Completed) BE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005575-12 Sponsor Protocol Number: BYON5667.002 Start Date*: 2021-06-30
    Sponsor Name:Byondis B.V.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular tox...
    Medical condition: Single arm run-in period: Patients with solid tumours (excluding gastric tumours and adenocarcinomas of the gastroesophageal junction) Randomized part of the study: patients with locally advanced ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000644-22 Sponsor Protocol Number: 2020PI198 Start Date*: 2021-06-25
    Sponsor Name:CHRU de Nancy
    Full Title: Effectiveness and Safety of Intra-Dermal Hepatitis B Vaccination after topical application of IMIQUIMOD, in cirrhotic patients, who did not respond to the conventional vaccine regimen: a pilot study
    Medical condition: Cirrhotic patients who have already received a HBV vaccination with a conventional regimen and who have not responded (characterized by a level of antibody Hbs < 10UI/ml at the end of the vaccine r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    21.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001780-37 Sponsor Protocol Number: * Start Date*: 2021-07-22
    Sponsor Name:Centre Hospitalier de Tourcoing
    Full Title: Prospective randomized controlled study of two antibiotic treatment times (3 versus 6 weeks) of diabetic foot osteomyelitis
    Medical condition: Patients de plus de 18 ans et de moins de 80 ans. Présentant une ostéite du pied diabétique.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10060803 Diabetic foot infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002224-20 Sponsor Protocol Number: 29BRC21.0131 Start Date*: 2021-07-09
    Sponsor Name:CHRU de Brest
    Full Title: PET / CT of pulmonary perfusion with Gallium68 for the preservation of pulmonary function during pulmonary stereotaxic radiotherapy.
    Medical condition: Non-small cell lung cancer (NSCLC) or lung metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003999-79 Sponsor Protocol Number: DRI13925 Start Date*: Information not available in EudraCT
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-co...
    Medical condition: Juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) CZ (Completed) ES (Ongoing) Outside EU/EEA EE (Completed) FI (Completed) NL (Completed) PL (Completed) DE (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001485-15 Sponsor Protocol Number: MYR204 Start Date*: 2019-09-24
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta
    Medical condition: Chronic Hepatitis Delta
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004789-17 Sponsor Protocol Number: RD.06.SPR.203065 Start Date*: 2020-07-08
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001801-56 Sponsor Protocol Number: VagDry001 Start Date*: 2021-09-29
    Sponsor Name:Gynial GmbH
    Full Title: Efficacy and Safety of a hyaluronic and lactic acid containing vaginal gel “HydroSanta® Vaginalgel” for the treatment of vaginal dryness symptoms – a multicenter randomized two-arm study
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000925-19 Sponsor Protocol Number: BAY80-6946/17322 Start Date*: 2015-03-23
    Sponsor Name:Bayer Healthcare AG
    Full Title: A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-2
    Medical condition: Patients with rituximab-refractory indolent non-Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IE (Completed) GR (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1724  1725  1726  1727  1728  1729  1730  1731  1732  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Sep 07 21:55:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA